<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To evaluate the efficacy and safety of initial therapy with a fixed-dose combination (<z:chebi fb="17" ids="38848">FDC</z:chebi>) of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> compared with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in drug-naÏve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: After a 2-week single-blind placebo run-in period, patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, HbA1c of 7.5-12% and not on antihyperglycaemic agent therapy were randomized in a double-blind manner to initial treatment with a <z:chebi fb="17" ids="38848">FDC</z:chebi> of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> 50/500 mg twice daily (N = 261) or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg per day (N = 256) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> were up-titrated over 4 weeks to doses of 50/1000 mg twice daily and 45 mg per day, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Both treatments were then continued for an additional 28 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: From a mean baseline HbA1c of 8.9% in both groups, least squares (LS) mean changes in HbA1c at week 32 were -1.9 and -1.4% for <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, respectively (between-group difference = -0.5%; p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>A greater proportion of patients had an HbA1c of &lt;7% at week 32 with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> vs. <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (57% vs. 43%, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> treatment resulted in greater LS mean reductions in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) [-56.0 mg/dl (-3.11 mmol/l) vs. -44.0 mg/dl (-2.45 mmol/l), p &lt; 0.001] and in 2-h post-meal <z:chebi fb="105" ids="17234">glucose</z:chebi> [-102.2 mg/dl (-5.68 mmol/l) vs. -82.0 mg/dl (-4.56 mmol/l), p &lt; 0.001] at week 32 </plain></SENT>
<SENT sid="7" pm="."><plain>A substantially greater reduction in FPG [-40.5 mg/dl (-2.25 mmol/l) vs. -13.0 mg/dl (-0.72 mmol/l), p &lt; 0.001] was observed at week 1 with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> vs. <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of β-cell function (HOMA-β) were observed with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> than with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, while greater decreases in fasting insulin and HOMA of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> than with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Both <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> were generally well tolerated </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="40237">Sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> led to <z:hpo ids='HP_0001824'>weight loss</z:hpo> (-1.4 kg), while <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> led to <z:mp ids='MP_0005456'>weight gain</z:mp> (3.0 kg) (p &lt; 0.001 for the between-group difference) </plain></SENT>
<SENT sid="11" pm="."><plain>Higher incidences of diarrhoea (15.3% vs. 4.3%, p &lt; 0.001), <z:hpo ids='HP_0002018'>nausea</z:hpo> (4.6% vs. 1.2%, p = 0.02) and <z:hpo ids='HP_0002013'>vomiting</z:hpo> (1.9% vs. 0.0%, p = 0.026), and a lower incidence of <z:hpo ids='HP_0000969'>oedema</z:hpo> (1.1% vs. 7.0%, p &lt; 0.001), were observed with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> vs. <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>The between-group difference in the incidence of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> did not reach statistical significance (8.4 and 4.3% with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, respectively; p = 0.055) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Compared with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, initial therapy with a <z:chebi fb="17" ids="38848">FDC</z:chebi> of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> led to significantly greater improvement in glycaemic control as well as a higher incidence of prespecified gastrointestinal adverse events, a lower incidence of <z:hpo ids='HP_0000969'>oedema</z:hpo> and <z:hpo ids='HP_0001824'>weight loss</z:hpo> vs. <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
</text></document>